Proton-pump inhibitors are the treatment of choice in acid-related disease

被引:2
|
作者
Brunner, G [1 ]
机构
[1] UNIV HANNOVER, SCH MED, DEPT MED, DIV GASTROENTEROL & HEPATOL, D-30167 HANNOVER, GERMANY
关键词
proton-pump inhibitors; H-2-receptor antagonists; acid-related disease;
D O I
10.1097/00042737-199610001-00003
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Increasing intragastric pH: Effective treatment of acid-related disease requires an increase in intragastric pH. The two principal pharmacological methods of attaining this goal are (1) using histamine (H-2)-receptor antagonists to block H-2-receptors on the parietal cell and (2) using proton-pump inhibitors to stop acid production acid at its source. H-2-receptor antagonists: H-2-receptor antagonists bind loosely and non-covalently to receptors on the parietal cell. They represented a great advance when they first appeared, bringing relief to many patients and improving the standard of care, with fewer operations and hospitalizations and a generally improved quality of life. However, many patients do not respond to these drugs, either because of the nature of the disease or because of resistance to the agent. Proton-pump inhibitors: Proton-pump inhibitors represent an advance in the therapy of acid-related disease because they inhibit all acid production, no matter what the source of the stimulus, by binding covalently to the proton pump. Compared with H-2-receptor antagonists, the effect of proton-pump inhibition is longer-lasting, faster-acting, and more effective, curing 99% of patients resistant to H-2-receptor antagonist therapy. These properties make proton-pump inhibitors the treatment of choice for acid-related diseases.
引用
收藏
页码:S9 / S13
页数:5
相关论文
共 50 条
  • [31] The appropriate use of proton-pump inhibitors
    Savarino, Vincenzo
    Marabotto, Elisa
    Zentilin, Patrizia
    Furnari, Manuele
    Bodini, Giorgia
    De Maria, Costanza
    Pellegatta, Gaia
    Coppo, Claudia
    Savarino, Edoardo
    MINERVA MEDICA, 2018, 109 (05) : 386 - 399
  • [32] Hypersensitivity reactions to proton-pump inhibitors
    不详
    ALLERGY AND ASTHMA PROCEEDINGS, 2020, 41 (02) : 144 - 144
  • [33] Antiprotozoal activity of proton-pump inhibitors
    Perez-Villanueva, Jaime
    Romo-Mancillas, Antonio
    Hernandez-Campos, Alicia
    Yepez-Mulia, Lilian
    Hernandez-Luis, Francisco
    Castillo, Rafael
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2011, 21 (24) : 7351 - 7354
  • [34] Proton-pump inhibitors and hypomagnesemic hypoparathyroidism
    Epstein, Martin
    McGrath, Shaun
    Law, Florence
    NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (17): : 1834 - 1836
  • [35] Tetany, Hypomagnesemia, and Proton-pump Inhibitors
    Famularo, Giuseppe
    Minisola, Giovanni
    Bravi, Maria Cristina
    Colucci, Pasquale
    Gasbarrone, Laura
    AMERICAN JOURNAL OF MEDICINE, 2012, 125 (10): : E7 - E8
  • [36] Anaphylactic reactions to proton-pump inhibitors
    Natsch, S
    Vinks, MHAM
    Voogt, AK
    Mees, EB
    Meyboom, RHB
    ANNALS OF PHARMACOTHERAPY, 2000, 34 (04) : 474 - 476
  • [37] Proton-pump inhibitors in managed care
    Frear, RS
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 1998, 55 (21) : 2249 - 2249
  • [38] Heartburn refractory to proton-pump inhibitors
    Trivedi A.
    Long J.D.
    Current Treatment Options in Gastroenterology, 2007, 10 (1) : 47 - 56
  • [40] Prevention of stress-related mucosal bleeding with proton-pump inhibitors
    Maton, PN
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2005, 22 : 45 - 52